Gilead invests US $32B to boost U.S. biotech

USA – Gilead Sciences has announced a major US $32 billion investment to expand its research and manufacturing operations in the United States.

The biopharmaceutical company says the move will generate up to US $43 billion in economic value over the next five years, thanks to direct capital spending and job creation.

This new investment includes an US $11 billion commitment on top of the US $21 billion Gilead already planned to spend through 2030 on U.S. manufacturing and research.

Together, these funds will enhance the company’s ability to develop innovative medicines while supporting American jobs and infrastructure.

As part of this phase, Gilead will build three new facilities and upgrade three existing sites. The goal is to strengthen its R&D and manufacturing footprint while introducing advanced technologies and engineering solutions.

Here’s how the US $11 billion will be used:

• US $4 billion will go into capital projects, including laboratories and high-tech equipment.
• US $5 billion is earmarked for operations, new technologies, and activities at R&D sites.
• US $2 billion will fund digital tools and advanced engineering efforts.

By 2028, the project is expected to create around 800 new direct jobs and support an additional 2,200 indirect roles. This initiative builds on Gilead’s past U.S. investments, which have totaled US $15 billion over the last decade.